Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Abstract Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible tyrosine kinase inhibitor with structural specificity for the catalytic domain...

ver descrição completa

Detalhes bibliográficos
Main Authors: Petros D. Grivas, Kathleen C. Day, Andreas Karatsinides, Alyssa Paul, Nazia Shakir, Iya Owainati, Monica Liebert, Lakshmi P. Kunju, Dafydd Thomas, Maha Hussain, Mark L. Day
Formato: Artigo
Idioma:English
Publicado em: BMC 2013-10-01
Colecção:Molecular Medicine
Assuntos:
Dacomitinib
Bladder Cancer Xenografts
Non-obese Diabetic/severe Combined Immunodeficiency (NOD/SCID)
Epidermal Growth Factor Receptor (EGFR)
Lapatinib
Acesso em linha:https://doi.org/10.2119/molmed.2013.00108

Internet

https://doi.org/10.2119/molmed.2013.00108

Registos relacionados